A Reliable Research Partner in Life Science and Medicine

Recombinant Human Coagulation Factor VII/F7 Protein (His Tag)

Catalog Number: PKSH031107

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source HEK293 Cells-derived Human Coagulation Factor VII/F7 protein Met 1-Pro 444, with

an C-terminal His

 Mol_Mass
 46.5 kDa

 Accession
 P08709-2

Bio-activity Not validated for activity

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.

Formulation Lyophilized from sterile PBS, pH 7.4


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Fax: 1-832-243-6017

Elabscience®

Elabscience Bionovation Inc.

A Reliable Research Partner in Life Science and Medicine

Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.

Fax: 1-832-243-6017